Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Canada — Health Canada

Tracked across 54 events · 768 articles · First seen Feb 13, 2025 · Last active Sep 23, 2026

Sentiment
6
Attention
7
Events
54
Relationships
14
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Regulatory
Impact: Regulatory authority that granted the expanded authorization, enabling the drug's use in breast cancer patients.
Aug 17, 2026 · 6 articles
4 20
Regulatory
Impact: Canada — Health Canada is the regulator that issued non-compliance ratings and imposed conditions on Grifols, leading to the pause. It is working to ensure compliance before allowing reopening.
Aug 13, 2026 · 6 articles
4 0
Business
Impact: Canada — Health Canada granted the Medical Device License to ClearPoint Neuro for its Neuro Navigation System, facilitating its use in Canadian neurosurgery centers.
Apr 20, 2026 · 6 articles
4 0
Regulatory
Impact: Canada — Health Canada is the regulatory body reviewing Diagnosis's CARA System application. Its guidance and approval are crucial for the system's market entry in Canada.
Jun 16, 2026 · 9 articles
2 0
Regulatory
Impact: Canada — Health Canada granted a Class II medical device licence to Diagnosis for the CARA System, marking a regulatory approval.
Jul 27, 2026 · 6 articles
2 0
Regulatory
Impact: Canada — Health Canada granted Notice of Compliance for Biocon's Yesintek autoinjector, following earlier approvals for other formulations. The regulator's decision enables a new treatment option for Canadian patients.
Jul 29, 2026 · 6 articles
2 0
Regulatory
Impact: Canada — Health Canada authorized VueJect under Medical Device License No. 115637, permitting its sale in Canada.
Aug 11, 2026 · 7 articles
2 0
Regulatory
Sahajanand Medical Technologies Limited (SMT) received a Class IV medical device license from Canada — Health Canada's Medical Devices Directorate for its Supraflex Cruz sirolimus-eluting coronary stent system. This approval allows the device to be…
Impact: Granted the Class IV medical device license, acting as the regulatory authority enabling SMT's market entry.
Sep 09, 2026 · 6 articles
1 0
Regulatory
Palisade Bio, Inc. (Nasdaq: PALI) announced that Canada — Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative…
Impact: Canada — Health Canada cleared Palisade Bio's Clinical Trial Application for ASCENTRA-UC, enabling clinical trial activities in Canada and expanding the study's geographic reach.
Sep 23, 2026 · 6 articles
4 40
Domestic
Impact: Canada — Health Canada is the government agency responsible for drug approval processes in Canada. Bill C-286 seeks to streamline its Special Access Program for psilocybin and psilocin, which has been criticized for slow and unpredictable approvals.
Jun 16, 2026 · 6 articles
2 0
Business
Impact: Canada — Health Canada is the regulatory body providing initial feedback to MedMira regarding the approval process for its Multiplo Complete Syphilis Antibody Test.
Jun 30, 2026 · 6 articles
4 50
Business
Impact: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.
Jun 08, 2026 · 14 articles
4 0
Business
Impact: Canada — Health Canada is the regulatory body whose approval is required for Medexus Pharmaceuticals to begin commercializing Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel in Canada.
Jun 10, 2026 · 6 articles
7 50
Tech
Impact: Canada — Health Canada>>> has not yet received an application to license daraxonrasib in Canada>>>. Its role is to regulate and approve new drugs for use in the country, impacting the timeline for Canadian patient access.
May 29, 2026 · 74 articles
4 0
Business
Impact: Diagnosis is pursuing regulatory clearance with Canada — Health Canada>>> for its CARA platform, a key milestone for market expansion in Canada.
Jun 05, 2026 · 11 articles
2 10
Domestic
Impact: Canada — Health Canada's recommendation in July 2025 facilitated provincial coverage decisions, playing a regulatory role in the drug's availability.
Aug 04, 2026 · 6 articles
2 0
Tech
Optimi Health announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial, authorized by Canada — Health Canada, will enroll up to 200 participants…
Impact: Canada — Health Canada authorized the clinical trial, enabling Optimi to proceed with the study. Its regulatory oversight is critical for the trial's legitimacy and future market authorization.
Sep 10, 2026 · 15 articles
2 0
Regulatory
Impact: Canada — Health Canada provided scientific advice on the trial design, consistent with its regulatory role; no direct impact on the agency.
Jul 06, 2026 · 6 articles
7 20
Accidents
Impact: Authorized Moderna's clinical trial, playing a regulatory role in vaccine development.
Aug 01, 2026 · 301 articles
2 0
Business
Impact: Canada — Health Canada approved WYNZORA in December 2025, a regulatory prerequisite for the launch.
Aug 20, 2026 · 6 articles
2 0
Tech
Abbott Laboratories announced on September 15, 2026 that its Volt Pulsed Field Ablation System was used for the first time in Canada at the McGill University Health Centre in Montreal to treat patients with atrial…
Impact: Canada — Health Canada authorized the Volt PFA System in April 2026, enabling its use in Canada and paving the way for this first procedure.
Sep 15, 2026 · 6 articles
2 0
Regulatory
Impact: Canada — Health Canada is the regulatory body in Canada to which Diagnosis plans to submit CARA for approval, impacting its commercialization in Canada.
Apr 08, 2026 · 6 articles
4 20
Tech
Impact: Canada — Health Canada approved the urgent application for exosome therapy on compassionate grounds, allowing the world-first treatment to proceed.
Jun 15, 2026 · 6 articles
4 10
Business
Impact: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.
Jun 02, 2026 · 25 articles
2 0
Business
Impact: Canada — Health Canada is the issuer of the Controlled Substances Dealer's Licence that Lophos Pharmaceuticals Corporation previously held, impacting the company's ability to conduct controlled substance activities.
Jun 12, 2026 · 6 articles
2 0
Accidents
Impact: Canada — Health Canada advises on safety guidelines for inflatable structures, and its recommendations are highlighted in the context of this accident.
Jun 02, 2026 · 6 articles
2 0
Regulatory
Impact: Canada — Health Canada's prior approval in July 2026 is referenced as a recent milestone, but it is not directly part of this event.
Aug 13, 2026 · 6 articles
2 0
Regulatory
Impact: Approved lecanemab in October 2025; not directly involved in funding decision.
Jul 16, 2026 · 7 articles
2 20
Business
Impact: Canada — Health Canada provides supportive regulatory frameworks that facilitate product approvals and market growth in Canada.
Jul 28, 2026 · 6 articles
1 10
Business
Impact: Canada — Health Canada approval for Kane's products enables commercial sales in Canada, contributing to the company's market presence.
Aug 05, 2026 · 7 articles
+ 24 more events View on Dashboard
Optimi Health ↔ Canada — Health Canada
Dane Stevens ↔ Canada — Health Canada
Optimi Health ↔ Canada — Health Canada
Dane Stevens ↔ Canada — Health Canada
Australia ↔ Canada — Health Canada
Australia ↔ Canada — Health Canada
Canada ↔ Canada — Health Canada
Canada ↔ Canada — Health Canada
United States ↔ Canada — Health Canada
United States ↔ Canada — Health Canada
United Kingdom ↔ Canada — Health Canada
United Kingdom ↔ Canada — Health Canada
ERGEN INTELLIGENCE
Track Canada — Health Canada live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.